{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=3", "query": { "intervention": "Open-Label Placebo", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1996, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open-Label+Placebo&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T07:33:27.066Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03065335", "title": "Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer", "Major Depressive Disorder", "Depression" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cobot TS MV robotic arm for TMS", "type": "DEVICE" }, { "name": "NeurOptics PLRTM-30000 Pupillometer", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DEVICE" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2017-05-25", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03065335" }, { "nct_id": "NCT05648110", "title": "Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19, SARS-CoV-2" ], "interventions": [ { "name": "AZD5156 (Parent study Sentinel Safety Cohort)", "type": "BIOLOGICAL" }, { "name": "Placebo (Parent study Sentinel Safety Cohort)", "type": "BIOLOGICAL" }, { "name": "EVUSHELD™ (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "AZD3152 (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "Placebo (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "AZD3152 (Sub-study)", "type": "BIOLOGICAL" }, { "name": "AZD7442 - EVUSHELD™ (Sub-study)", "type": "BIOLOGICAL" }, { "name": "AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "12 Years to 130 Years" }, "enrollment_count": 3882, "start_date": "2022-12-16", "completion_date": "2025-02-11", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 130, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05648110" }, { "nct_id": "NCT01590459", "title": "24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "VX-509", "type": "DRUG" }, { "name": "VX-509 matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 359, "start_date": "2012-04", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01590459" }, { "nct_id": "NCT04394351", "title": "Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "11 Years", "sex": "ALL", "summary": "1 Year to 11 Years" }, "enrollment_count": 102, "start_date": "2020-09-01", "completion_date": "2024-05-14", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04394351" }, { "nct_id": "NCT01672866", "title": "Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Fibrosis Due to NASH" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "SIM", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 222, "start_date": "2012-12-05", "completion_date": "2016-12-29", "has_results": true, "last_update_posted_date": "2019-03-27", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Coronado, California • San Diego, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01672866" }, { "nct_id": "NCT02346422", "title": "A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ischemic Cardiomyopathy", "Non-ischemic Cardiomyopathy", "Heart Failure", "Cardiomyopathies" ], "interventions": [ { "name": "MYDICAR Phase 1", "type": "GENETIC" }, { "name": "MYDICAR Phase 2", "type": "GENETIC" }, { "name": "Placebo Phase 2 only", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Celladon Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 9, "start_date": "2015-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-01-31", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 4, "location_summary": "La Jolla, California • San Diego, California • Kansas City, Missouri + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346422" }, { "nct_id": "NCT01140451", "title": "Extension Study of Ataluren (PTC124) in Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ataluren", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PTC Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 191, "start_date": "2010-08-12", "completion_date": "2013-12-02", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Long Beach, California • Palo Alto, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01140451" }, { "nct_id": "NCT03437941", "title": "Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Exicorilant", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 39, "start_date": "2018-02-20", "completion_date": "2023-01-12", "has_results": true, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03437941" }, { "nct_id": "NCT02445339", "title": "Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Alcohol Dependence", "Alcohol Use Disorder" ], "interventions": [ { "name": "XR-NTX+CM (Extended-Release Naltrexone plus Care Management)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 50, "start_date": "2015-07", "completion_date": "2019-02-08", "has_results": true, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02445339" }, { "nct_id": "NCT02397694", "title": "Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "BIC", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "BIC Placebo", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2015-03-23", "completion_date": "2019-02-27", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-19T07:33:27.066Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02397694" } ] }